Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan and Tadalafil in PAH-SSc
NCT01042158Phase 4Completed
- Sponsor
- Johns Hopkins University
- Start
- Jan 2010
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ambrisentan, tadalafil in pulmonary arterial hypertension (PAH), sponsored by Johns Hopkins University. Started Jan 2010; status: completed.
02
Drugs
ambrisentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01042158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01042158.